
- /
- Supported exchanges
- / SA
- / D1EX34.SA
DexCom Inc. (D1EX34 SA) stock market data APIs
DexCom Inc. Financial Data Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get DexCom Inc. data using free add-ons & libraries
Get DexCom Inc. Fundamental Data
DexCom Inc. Fundamental data includes:
- Net Revenue: 4 148 M
- EBITDA: 858 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-23
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DexCom Inc. News

Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 34% Discount?
Key Insights The projected fair value for DexCom is US$127 based on 2 Stage Free Cash Flow to Equity DexCom is estimated to be 34% undervalued based on current share price of US$84.10 The US$98.85 an...


Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.The powerful, high-ener...

Edgepark expands diabetes offerings with two new product innovations
Explore the latest in diabetes management solutions, including over-the-counter offerings and first-of-their-kind products TWINSBURG, Ohio, July 15, 2025 /PRNewswire/ -- Edgepark has recently expande...

Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
MarketNewsUpdatesNews Commentary NEW YORK, July 15, 2025 /CNW/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-r...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.